Medeon Biodesign (ROCO:6499) Beta: 0.4732 (As of Jul. 13, 2026)


ROCO:6499 Medeon Biodesign Inc ROCO:6499
68 GF Score
Price NT$69.80
GF Value NT$107.08
Valuation Significantly Undervalued
! 1 Warning Sign
View Full Analysis

What is Medeon Biodesign Beta?

Author: Vera Yuan Vera Yuan Reviewed by: Charlie Tian Charlie Tian

Medeon Biodesign ROCO:6499 -1.69% 68 Beta is 0.4732 as of Jul. 13, 2026. GuruFocus rates ROCO:6499 with a GF Score™ of 68/100 and a GF Value™ of NT$107.08 (Significantly Undervalued). The stock has 1 warning sign investors should review.

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. As of today (2026-07-13), Medeon Biodesign's Beta is 0.4732.


Medeon Biodesign  (ROCO:6499) Beta Explanation

Beta is a measure of the volatility, or systematic risk, of a security or a portfolio in comparison to the market as a whole. We usually compare beta to 1. A beta of 1 indicates that the security's price will move with the market. A beta of less than 1 means that the security will be less volatile than the market. A beta of greater than 1 indicates that the security's price will be more volatile than the market.

Beta is primarily used in the Capital Asset Pricing Model (CAPM) to calculate the Cost of Equity, which can be used in the calculation of WACC %. The formula of Cost of Equity is:
Cost of Equity = Risk-Free Rate of Return + Beta of Asset * (Expected Return of the Market - Risk-Free Rate of Return)


Medeon Biodesign Beta Related Terms


Medeon Biodesign Beta Historical Data

* Premium members only.

The historical data trend for Medeon Biodesign's Beta can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Medeon Biodesign Beta Chart

Medeon Biodesign Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Beta
Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.47 1.06 0.74 0.47 0.00

Medeon Biodesign Quarterly Data
Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25
Beta Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.47 0.00 0.00 0.00 0.00

ROCO:6499 vs ISRG, BDX, MDLN: Beta Comparison

For the Medical Instruments & Supplies subindustry, Medeon Biodesign's Beta, along with its competitors' market caps and Beta data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Medeon Biodesign Beta vs Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, Medeon Biodesign's Beta distribution charts can be found below:

* The bar in red indicates where Medeon Biodesign's Beta falls into.


ROCO:6499
68GF Score
Medeon Biodesign Inc ROCO:6499
Beta is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Medeon Biodesign Beta Calculation

Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. A stock's beta can be calculated by dividing the product of the covariance of the individual stock's returns and the market's returns by the variance of the market's returns over a specified period. Basically, GuruFocus uses the returns calculated over three-year period.

Frequently Asked Questions Learn more about Beta →
What does a Beta of 0.4732 mean?
Medeon Biodesign (ROCO:6499) has a Beta of 0.4732 as of Jul. 13, 2026. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medeon Biodesign and its competitors.
Is Medeon Biodesign's Beta too high?
Medeon Biodesign's current Beta is 0.4732. Overall, Medeon Biodesign has a GF Score™ of 68/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Medeon Biodesign's Beta compare to ISRG and BDX?
Medeon Biodesign's Beta of 0.4732 can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Beta for a Medical Devices & Instruments company?
A good Beta depends on the Medical Devices & Instruments industry context. However, Beta should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Beta mean?
A high Beta can signal that a stock is expensive relative to its fundamentals. Beta is the sensitivity of the expected excess asset returns to the expected excess market returns. View historical data for Medeon Biodesign and its competitors. Medeon Biodesign's current Beta is 0.4732. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Medeon Biodesign stock overvalued right now?
Based on GuruFocus' analysis, Medeon Biodesign (ROCO:6499) is currently considered Significantly Undervalued. The stock's GF Value™ is NT$107.08, compared to a current price of NT$69.80 — trading 34.8% below its estimated fair value. The current Beta is 0.4732. Medeon Biodesign's overall GF Score™ is 68/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Beta calculated?
Beta is calculated from a company's financial statements. For Medeon Biodesign (ROCO:6499), the current Beta is 0.4732 as of Jul. 13, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Medeon Biodesign (ROCO:6499) Overvalued in 2026?

Based on GuruFocus' analysis, Medeon Biodesign stock appears to be undervalued. The current stock price of NT$69.80 is trading 34.8% below its estimated GF Value™ of NT$107.08. GuruFocus considers Medeon Biodesign to be Significantly Undervalued.

Key valuation signals for ROCO:6499:

  • Beta: 0.4732
  • GF Value™: NT$107.08 vs. price of NT$69.80 (34.8% below fair value)
  • GF Score™: 68/100 with 1 warning sign

No single metric tells the full story. See the ROCO:6499 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.


Medeon Biodesign Business Description

Address No. 116, HouGang Street, 7th Floor, Shilin District, Taipei, TWN, 11170
Medeon Biodesign Inc develops medical device products. The main services of the Group are the research and development of medical devices, manufacturing, and sale of injection molding and components of medical devices. The company provides products in the fields of cardiovascular and laparoscopic. Its business includes Medical Device Development Department and Medical Device Components Manufacturing and Sales Department. The majority of the company revenue comes from Medical Device Components Manufacturing and Sales Department segment. The company revenue is mainly derived from the USA.
68GF Score

Get the complete analysis for ROCO:6499

Beta is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

NT$69.80
Price
NT$107.08
GF Value